Theraflu Extra Lemon 650mg+10mg+20mg powder for oral solution with lemon flavour

Land: Armenië

Taal: Engels

Bron: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Download Productkenmerken (SPC)
05-06-2019

Werkstoffen:

paracetamol, phenylephrine (phenylephrine hydrochloride), pheniramine (pheniramine maleate)

Beschikbaar vanaf:

Famar Orleans

ATC-code:

N02BE51

INN (Algemene Internationale Benaming):

paracetamol, phenylephrine (phenylephrine hydrochloride), pheniramine (pheniramine maleate)

Dosering:

650mg+10mg+20mg

farmaceutische vorm:

powder for oral solution with lemon flavour

Eenheden in pakket:

(10) sachets 15g

Prescription-type:

OTC

Autorisatie-status:

Registered

Autorisatie datum:

2019-06-05

Productkenmerken

                                N O V A R T I S
Global Drug Regulatory Affairs
THERAFLU EXTRA LEMON
Powder in Sachets
Actives substances
Paracetamol 650mg; Pheniramine maleate 20mg;
Phenylephrine hydrochloride 10mg;
SUMMARY OF PRODUCT CHARACTERISTICS
Property of Novartis Consumer Health
SA Confidential
May not be used, divulged, published or otherwise
disclosed without the consent of Novartis Consumer Health
SA
TABLE OF CONTENTS
1.
NAME OF THE MEDICINAL PRODUCT
.........................................................................
3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
.............................................. 3
3.
PHARMACEUTICAL FORM
..............................................................................................
3
4.
CLINICAL PARTICULARS
.................................................................................................
3
4.1 THERAPEUTIC INDICATIONS
................................................................................................
3
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
................................................................... 3
4.3.
CONTRAINDICATIONS
.......................................................................................................
3
4.4.
SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
.................................................... 4
4.5.
INTERACTIONS WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION ......... 4
4.6.
PREGNANCY AND LACTATION
.............................................................................................
5
4.7.
EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
............................................................ 5
4.8.
UNDESIRABLE EFFECTS
.......................................................................................................6
4.9.
OVERDOSE
.......................................................................................................................
6
5.
PHARMACOLOGICAL PROPERTIES
..............................................................................
7
5.1.
PHARMACODYNA
                                
                                Lees het volledige document
                                
                            

Documenten in andere talen

Bijsluiter Bijsluiter Russisch 05-06-2019